Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer
NCT ID: NCT03384667
Last Updated: 2018-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
96 participants
INTERVENTIONAL
2018-02-22
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MMDT group
Maekmoondong-tang
MMDT is a Herbal medicine consist of six herbs.
Placebo group
Placebo
The granules do not contain any active ingredients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Maekmoondong-tang
MMDT is a Herbal medicine consist of six herbs.
Placebo
The granules do not contain any active ingredients.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergone segmentectomy or lobectomy for lung cancer within 1 month
* Patients who do not or poorly respond to one week administration of common antitussive agents.
* Eastern Cooperative Oncology Group(ECOG) 0 to 2
* Participant is willing and able to give informed consent for participation in the study
Exclusion Criteria
* Patients who have been diagnosed with acute respiratory disease within 1 month.
* Patients who have been diagnosed with bronchial asthma or bronchiectasis within 1 year
* Patients taking Angiotensin Converting Enzyme Inhibitor
* Patients with pseudoaldosteronism.
* Participants who have known prior hypersensitivity to any investigational product component
* Patient with acute or chronic infections requiring treatment (active HAV, HBV, HCV, HIV, TB)
* Pregnant or lactating females
* Women of childbearing potential
* Patient who do not agrees to use effective means of contraception and not to donate sperm during the trial and up to 1 month after final administration
* Patient who participated other clinical trials of medicine or medical devices within 1 month
* Individuals who are judged inappropriate for the study by investigator
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seong-Gyu Ko
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seong-Gyu Ko
Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Guro Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hyojin Son
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ISEE_MMDT_2017
Identifier Type: -
Identifier Source: org_study_id